Radar

Radar

The field read on diabetes. A monthly report — the editorial read across the month's source-worlds, with every item graded by where its evidence comes from.

Monthly report

The flagship — a month of the field read across its source-worlds, each item graded by where its evidence comes from. Published monthly.

Jul Monthly · No. 2 · July 2026 The pipeline stops arguing about efficacy A triple agonist heads for the regulators, the oral race becomes a question of factories and capital, incretins are tested in addiction medicine, and the tolerability ledger keeps growing. Open the issue → Jun Monthly · No. 1 · June 2026 Disease modification arrives — and the system starts counting the cost Teplizumab reaches newly diagnosed children, the GLP-1 bill comes due, and the science narrows on whom to treat. Open the issue →
∑ Running index Every trial we have covered What each one showed, what it did not, and which have not reported. Built from the issues, so it updates itself. Open the index →
Weekly brief · archive 2 issues, 2026

A short-run weekly pulse from mid-2026. The cadence is monthly now; these two stay here as published, audio and all.

27 Week 27 · 2026 From Insulin Management to Disease Modification — Pediatric T1D's Turning Point FDA's pediatric teplizumab approval and the first OTC CGM for children signal a structural shift in type 1 diabetes care — while generic tirzepatide and metabolic mechanism research reshape the broader field. Read the brief → 26 Week 26 · 2026 The Oral and Next-Gen Incretin Field Goes Wide Registrations push incretin biology into new oral agents, new comparators, and indications well beyond glycemia. Read the brief →

A question worth thinking through together?

For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.

Request a confidential scoping call

Prefer email? [email protected]